



## Exploring the Relationship between PheSA Scores and Ligand Efficiency in the Discovery of Potent Antimalarials: A Computational Perspective

**Agede Olalekan Ayodele<sup>1,2\*</sup>, Ogunmodede James Ayodele<sup>2</sup>, Sanni Nasiru<sup>2</sup>,  
Wasagu Isa Musa<sup>3</sup>, Oyedepo Dapo Sunday<sup>2</sup>, Aiyedun Olawale Stephen<sup>2</sup>,  
Falade Catherine Olufunke<sup>4</sup>**

<sup>1</sup>Department of Pharmacology and Therapeutics, University of Ilorin, Nigeria

<sup>2</sup>Department of Medicine, University of Ilorin and University of Ilorin Teaching Hospital, Ilorin, Nigeria

<sup>3</sup>Department of Medicine, Usmanu Dan Fodiyo University Teaching Hospital, Sokoto, Nigeria


<sup>4</sup>Department of Pharmacology and Therapeutics, University of Ibadan, Nigeria

\*Corresponding author: [niffynimmy@yahoo.com](mailto:niffynimmy@yahoo.com) & [agede.oa@unilorin.edu.ng](mailto:agede.oa@unilorin.edu.ng)


### Supplementary Material

## List of Figures

<b>Figure</b>	<b>Content</b>	<b>Page</b>
S1	Positive HRESI-MS spectrum of compound <b>1</b>	3
S2	Positive HRESI-MS/MS spectrum of compound <b>1</b>	4
S3	<sup>1</sup> H NMR spectrum (CD <sub>3</sub> OD, 500 MHz) of compound <b>1</b>	5




### S1. Novel cycloguanil derivatives based on de novo synthesis




a

■ High ■ Low ■ None




b

■ High ■ Low ■ None



c











■ High ■ Low ■ None



d

■ High ■ Low ■ None

**S2. Toxicity screening based on (a) Mutagenic (b) Tumorigenic (c) Reproductive and (d) Irritant properties**

<p>Compound 1</p>  <p>PheSA similarity: 0.84304</p>	<p>Compound 2</p>  <p>PheSA similarity: 0.8412</p>	<p>Compound 3</p>  <p>PheSA similarity: 0.83938</p>	<p>Compound 4</p>  <p>PheSA similarity: 0.83921</p>	<p>Compound 5</p>  <p>PheSA similarity: 0.83847</p>
<p>Compound 6</p>  <p>PheSA similarity: 0.83847</p>	<p>Compound 7</p>  <p>PheSA similarity: 0.83778</p>	<p>Compound 8</p>  <p>PheSA similarity: 0.8376</p>	<p>Compound 9</p>  <p>PheSA similarity: 0.83732</p>	<p>Compound 10</p>  <p>PheSA similarity: 0.8373</p>

### S3. Novel compounds with higher PheSA sharing the same core fragment as cycloguanil